Latest news in cancer
Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions
August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET...
Trifluridine and tipiracil with bevacizumab is approved by FDA for previously treated metastatic colorectal cancer
The Food and Drug Administration approved trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer (mCRC)...
Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer
The Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent...
Quizartinib is approved by the FDA for newly diagnosed acute myeloid leukemia
The Food and Drug Administration approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine...
A trial shows that blinatumomab could be used in more ways to treat ALL
BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable...
Development and future potential of the BiTE (bispecific T-cell engager) platform
Immuno-oncology is a way to treat cancer by using the body's immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform...
Rare autoimmune disorder myasthenia gravis treated by CAR-T therapy
The modified CAR-T treatment, which stands for chimeric antigen receptor T-cell, was used by scientists. It could reduce myasthenia gravis symptoms for a...
Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated...
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large...
Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or...
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large...
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.